Innovative Drug Discovery Model

Cell Therapy Manufacturing Facility

MD Anderson’s Cell Therapy Manufacturing Facility (CTMF) is a state-of-the-art laboratory which provides industrial drug-development expertise to advance cell therapy programs from laboratory concepts to commercializable therapeutics. Acquired in 2020, the CTMF is located just blocks from MD Anderson’s main hospital, making it an ideal facility to bring together the world-class research and unmatched clinical care that MD Anderson has to offer.

The CTMF is managed by MD Anderson’s Biologics Development team, part of the Therapeutics Discovery division. It is led by an experienced biopharmaceutical team with a combined 150 years of industry experience. The staff of industry veterans and MD Anderson scientists creates a unique culture of innovation and industrial good manufacturing practices (GMPs) with expertise in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, endogenous T-cell (ETC) therapy as well as other emerging and enabling cell-therapy modalities. The GMP facility boasts 11 clean rooms, 30,000 square feet of BSL-2+ clean rooms, and support space for Proof of Concept trials, pivotal trials and commercial launch, as needed. Additionally, three GMP clean rooms are located on a separate floor and serve as an ideal venue for viral vector manufacturing.

Biologics Development works closely with leading MD Anderson clinicians and researchers to help define the leading edge of cell therapies and rapidly advance products to patients and clinical proof-of-concept. Biologics Development also engages in strategic collaborations to co-develop innovative products, rapidly utilizing the expansive MD Anderson ecosystem.